Oxford Nanopore Technologies has raised £29.3M ($38.6M) in new capital and additionally facilitated the sale of £80.2M ($105.9) in secondary shares, resulting in total gross proceeds of £109.5M ($144.5M).
These funds have been raised internationally and include both new investors and existing shareholders, from the US, Europe and Asia/Pacific.
This brings the total primary investment in Oxford Nanopore to ~£480M to date.
Further information on Oxford Nanopore’s fundraising will be made available in due course.
The Company made substantial progress in 2019; from scaling up to population-scale sequencing with PromethION, to accurate, rapid testing in cancer and infectious disease.
USD amounts assume exchange rate of 1.32 at 31st December 2019.
Related Reports and Monitors
Butterfly Network iQ CMUT Sensor
Reverse Costing - Structural, Process & Cost Report
Point-of-Need 2020 – Including PCR-Based Testing
Market & Technology